Elevance Health Inc
Ownership
Ownership Structure
Who owns Elevance Health Inc (ELV)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 99.4% of the shares are freely tradable; institutional investors hold 93.4%.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| BlackRock Inc | 8.76 | 18,991,090 | -4.5 | 06/30/2026 |
| Vanguard Capital Management, LLC | 6.48 | 14,058,204 | -2.0 | 06/30/2026 |
| State Street Corp | 4.81 | 10,426,610 | +1.3 | 06/30/2026 |
| Wellington Management Company LLP | 4.25 | 9,213,513 | +12.0 | 06/30/2026 |
| Arnhold & S. Bleichroeder Advisers, LLC | 3.86 | 8,376,392 | +102.7 | 06/30/2026 |
| Vanguard Portfolio Management, LLC | 2.87 | 6,214,356 | -2.2 | 06/30/2026 |
| Sanders Capital, LLC | 2.69 | 5,825,024 | -1.2 | 06/30/2026 |
| Geode Capital Management, LLC | 2.38 | 5,166,124 | -0.5 | 06/30/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 3.09 | 6,705,479 | -1.0 | 09/30/2026 |
| Vanguard 500 Index Investor | 2.56 | 5,544,719 | -2.1 | 09/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insider holdings
| Person | Role | Shares | Value | As of | Type |
|---|---|---|---|---|---|
| Boudreaux Gail | President and CEO | 171,976 | 72,247,118 $ | Jul 17, 2026 | direct |
| Kaye Mark | EVP & CFO | 19,919 | 8,367,972 $ | Oct 22, 2026 | direct |
| Peru Ramiro G | Director | 10,908 | 4,582,451 $ | Jul 17, 2026 | direct |
| Wessling Erin M | EVP & Chief Legal Officer | 7,230 | 3,037,323 $ | Sep 3, 2026 | direct |
| Craig Ryan R | EVP & Chief HR Officer | 6,530 | 2,743,253 $ | Sep 2, 2026 | direct |
Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.
Insiders
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Oct 22, 2026 | Kaye Mark | EVP & CFO | Sell | 273 | 447.19 | 122,083 |
| Oct 22, 2026 | Kaye Mark | EVP & CFO | Sell | 827 | 446.05 | 368,883 |
| Oct 22, 2026 | Kaye Mark | EVP & CFO | Sell | 160 | 444.85 | 71,176 |
| Oct 22, 2026 | Kaye Mark | EVP & CFO | Sell | 440 | 443.81 | 195,276 |
| Oct 22, 2026 | Kaye Mark | EVP & CFO | Sell | 480 | 442.61 | 212,453 |
| Oct 22, 2026 | Kaye Mark | EVP & CFO | Sell | 2,343 | 441.34 | 1,034,060 |
| Oct 22, 2026 | Kaye Mark | EVP & CFO | Sell | 1,720 | 440.44 | 757,557 |
| Oct 22, 2026 | Kaye Mark | EVP & CFO | Sell | 1,160 | 439.25 | 509,530 |
| Oct 22, 2026 | Kaye Mark | EVP & CFO | Sell | 240 | 438.22 | 105,173 |
| Oct 22, 2026 | Kaye Mark | EVP & CFO | Sell | 560 | 437.07 | 244,759 |
| Oct 22, 2026 | Kaye Mark | EVP & CFO | Sell | 1,660 | 436.20 | 724,092 |
| Oct 22, 2026 | Kaye Mark | EVP & CFO | Sell | 321 | 435.25 | 139,715 |
| Oct 22, 2026 | Kaye Mark | EVP & CFO | Sell | 400 | 434.00 | 173,600 |
| Oct 2, 2026 | Kaye Mark | EVP & CFO | Other | 2,627 | 0.00 | – |
| Oct 2, 2026 | Kaye Mark | EVP & CFO | Other | 4,161 | 386.43 | 1,607,935 |
| Sep 3, 2026 | Wessling Erin M | EVP & Chief Legal Officer | Other | 255 | 414.78 | 105,769 |
| Sep 2, 2026 | Wessling Erin M | EVP & Chief Legal Officer | Other | 94 | 405.84 | 38,149 |
| Sep 2, 2026 | Craig Ryan R | EVP & Chief HR Officer | Other | 144 | 405.84 | 58,441 |
| Jul 17, 2026 | Boudreaux Gail | President and CEO | Buy | 2,045 | 368.25 | 753,071 |
| Jul 17, 2026 | Boudreaux Gail | President and CEO | Buy | 680 | 366.41 | 249,159 |
| Jul 17, 2026 | Peru Ramiro G | Director | Buy | 1,000 | 366.05 | 366,050 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →
Data as of: October 30, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.